Skip to content
Screener

Exelixis EXEL Share Buybacks

Share Buybacks at other companies

Eli Lilly logo
Eli LillyLLY
$1.6B+131%
Opko Health logo
Opko HealthOPK
$13.02M-28.7%
Gilead Sciences logo
Gilead SciencesGILD
$355M-32.6%
United Therapeutics logo
United TherapeuticsUTHR
$1.5B

Other financials

Income statement

See full
Revenue$628.7M+10.6%
Gross profit$608.0M+10.8%
Operating income$248.4M+16.3%
Net income$212.1M+14.7%
EPS (diluted)$0.82+26.2%

Balance sheet

See full
Cash & equivalents$281.4M+71.2%
Total debt$165.9M-7.7%
Total equity$1.8B-9.3%
Total assets$2.5B-6.9%

Cash flow

See full
Operating cash flow$307.7M+528%
CapEx$6.8M+140%
Free cash flow$300.9M+552%

Valuation

See full
Market cap$14.25B+40.4%
Enterprise value$14.14B+39.0%
P/E16.6×-0.3×
P/S5.9×+1.3×

Profitability

See full
Gross margin96.5%-0.1pp
Operating margin39.9%+8.5pp
Net margin35.3%+8.3pp
FCF margin48.1%+14.3pp

Returns & leverage

See full
Return on equity44.4%+15.4pp
Debt / equity0.1×0.0×
Current ratio3.5×-0.1×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.

The source filing: Exelixis’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q3 2026
Accession
0000939767-26-000098
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Acquired in-process research and development technology(3,025)(20,250)
Net cash provided by investing activities40,360297,795
Cash flows from financing activities:
Payments for repurchases of common stock(753,326)(585,858)
Proceeds from issuance of common stock under the equity incentive plan and stock purchase plan22,91237,710
Taxes paid related to net share settlement of equity awards(70,572)(63,018)
Net cash used in financing activities(800,986)(611,166)
Net decrease in cash and cash equivalents(201,040)(52,941)

Item 1. Financial Statements.

FAQ

What is Exelixis's share buybacks?
Exelixis (EXEL) reported share buybacks of $322.97M in Q2 2026.
How has Exelixis's share buybacks changed year-over-year?
Exelixis's share buybacks increased by 7.0% year-over-year, from $301.92M to $322.97M.
What does share buybacks mean?
Cash used to buy back the company's own shares on the open market or through structured programs, reducing shares outstanding.

Ask your AI about Exelixis's share buybacks.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude